Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.

摘要: Abstract Neratinib is an irreversible, pan-human epidermal growth factor inhibitor that has shown efficacy across human receptor 2 (HER2)-positive breast cancer settings. indicated for use as extended adjuvant therapy HER2-positive early-stage or, in combination with capecitabine, the treatment of metastatic cancer. The primary tolerability concern neratinib diarrhea, and severe diarrhea early can lead to a substantial proportion patients discontinuing neratinib, which may reduced or nonexistent efficacy. In order establish set recommendations on May 12, 2020, expert panel oncologists gastroenterologists met virtually discuss role reviewed current data including settings management strategies. Based these their clinical experience, panelists developed guide selection implement weekly dose escalation at initiation therapy, prophylactically manage diarrhea.